Kinesid Therapeutics

Kinesid Therapeutics is a biotechnology company focused on the discovery and development of small molecule therapeutics targeting the kinesin superfamily of motor proteins. These proteins are critical for intracellular transport, and their impairment is a hallmark of several neurodegenerative conditions and oncological processes. The company's primary focus is on developing modulators for KIF5A to treat Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). By leveraging its deep expertise in kinesin biology and a proprietary discovery platform, Kinesid aims to restore cellular transport mechanisms and provide transformative treatments for patients with limited options. The leadership team comprises industry veterans with significant experience in protein degradation and motor protein research.